Oncology

 

Oncology

Measuring Biomarkers
at Every Stage
of Tumor Development

The ability to detect oncology biomarkers at ultra-low levels has the potential to enable new options for diagnostics and treatment in cancer research.

Simoa assays have the potential to be used to monitor cancer risk, identify early-stage cancers and discriminate between benign and malignant cells. Simoa biomarkers also have the potential to be used prognostically to predict disease outcome, predict progression-free survival and monitor reoccurrence, and to be used to monitor sensitivity to therapy and to aid in treatment decisions.

Latest Publications

Quanterix' digital health solution, Simoa, is changing the way researchers, academics and drug manufacturers measure and detect various forms of cancer at the earliest stage. Quanterix' focus in oncology is growing with a network of academic researchers and pharmaceutical and biotech partners. Learn about Simoa's application in oncology by exploring our scientific publications and journals.

Latest News

01.10
Following successful beta program, the Simoa SP-X next generation benchtop and CorPlex are launching ahead of schedule to further revolutionize cancer research, immunotherapy monitoring, and drug development
01.09
The Quanterix SP-X Imaging and Analysis System is the first complete benchtop system offering true multiplex detection capabilities at both acute and baseline levels.